...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical science monitor : >Blood concentration of plasmin-alpha 2 antiplasmin complexes in patients with non-small-cell lung cancer
【24h】

Blood concentration of plasmin-alpha 2 antiplasmin complexes in patients with non-small-cell lung cancer

机译：非小细胞肺癌患者血浆纤溶酶-α2抗纤溶酶复合物的血药浓度

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The determination of plasmin-alpha 2 antiplasmin complexes (PAP) is a peripheral marker of plasminogenesis taking place in vivo. Due to the key role of plasmin in the pathogenesis of malignancy, the aim of the present study was to evaluate the level of PAP complexes and the activity of alpha 2 antiplasmin in the blood of patients with non-small-cell lung cancer. Test group consisted of 46 patients at mean age of 58 years, out of whom 16 displayed II and 30 - III stadium of the advancement of neoplastic process. Significant increase in blood concentration of PAP complexes was observed in patients with lung cancer, which indicates the presence of intensive plasminogenesis. Blood levels of PAP complexes were significantly higher in patients with III than in those with II stage of neoplasm advancement. The activity of alpha 2 antiplasmin was significantly higher in patients with lung cancer when compared with healthy subjects, but it did not exceed physiological values.
机译：纤溶酶α2抗纤溶酶复合物（PAP）的确定是体内发生纤溶酶发生的外围标志。由于纤溶酶在恶性肿瘤发病机制中的关键作用，本研究的目的是评估非小细胞肺癌患者血液中PAP复合物的水平和α2抗纤溶酶的活性。试验组由46名平均年龄58岁的患者组成，其中16名患者显示了II和30-III肿瘤过程的进展。在肺癌患者中观察到PAP复合物的血药浓度显着增加，表明存在强烈的纤溶酶发生。 III级患者的PAP复合物的血液水平显着高于II级肿瘤进展的患者。与健康受试者相比，肺癌患者中α2抗纤溶酶的活性明显更高，但未超过生理值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号